Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.93)
# 1,418
Out of 5,149 analysts
137
Total ratings
53.64%
Success rate
31.05%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $23.94 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $64.33 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $790.81 | +7.48% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $2.15 | +739.16% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.08 | +5,455.56% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.66 | +238.35% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $5.82 | +484.19% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $188.05 | +73.89% | 7 | Oct 15, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $58.02 | +878.97% | 2 | Jun 14, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $285 → $281 | $486.03 | -42.18% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.26 | +534.92% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.50 | +6,433.33% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $385.70 | -23.52% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $150.03 | -42.68% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $29.40 | +63.27% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $5.73 | +423.56% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $29.20 | +146.58% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.62 | +208.64% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $100.04 | -0.04% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $242.09 | -16.97% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $66.37 | +28.07% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $14.21 | +125.19% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $16.32 | +1,229.66% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $54.91 | -12.58% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $14.51 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $325.07 | -52.63% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $59.74 | +94.17% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $6.42 | +1,551.09% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $15.44 | +81.35% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $209.87 | -60.93% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $513.82 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.88 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.94
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $64.33
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $790.81
Upside: +7.48%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $2.15
Upside: +739.16%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.08
Upside: +5,455.56%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.66
Upside: +238.35%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $5.82
Upside: +484.19%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $188.05
Upside: +73.89%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $58.02
Upside: +878.97%
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $486.03
Upside: -42.18%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.26
Upside: +534.92%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.50
Upside: +6,433.33%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $385.70
Upside: -23.52%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $150.03
Upside: -42.68%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $29.40
Upside: +63.27%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $5.73
Upside: +423.56%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $29.20
Upside: +146.58%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.62
Upside: +208.64%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $100.04
Upside: -0.04%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $242.09
Upside: -16.97%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $66.37
Upside: +28.07%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $14.21
Upside: +125.19%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $16.32
Upside: +1,229.66%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $54.91
Upside: -12.58%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $14.51
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $325.07
Upside: -52.63%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $59.74
Upside: +94.17%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $6.42
Upside: +1,551.09%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $15.44
Upside: +81.35%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $209.87
Upside: -60.93%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $513.82
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.88
Upside: -